rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ACET
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Adicet Bio announces board changes and committee appointments
      Nov 13Investing.comACET
      Adicet Bio (ACET) Stock Fair Value Moves Lower After Prula Cel Lupus Data

      The fair value range that analysts use for Adicet Bio has been revised from about US$34.83 to US$29.00. This change resets where many models now anchor the stock. The revision is linked directly to the latest prula cel data in systemic lupus erythematosus and lupus nephritis, as well as differing views on how much of that potential is already captured in the current share price. As you read on, you will see how this evolving narrative may influence how you track Adicet Bio from here. Analyst...

      Nov 11Yahoo FinanceACET
      Adicet Bio at Guggenheim conference: lupus data lifts pivotal hopes
      Nov 10Investing.comACET
      Adicet Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates
      Nov 5Yahoo FinanceACET
      Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

      REDWOOD CITY, Calif., October 30, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced it granted an inducement award on October 30, 2026.

      Oct 30Yahoo FinanceACET
      Adicet Bio to Participate in Upcoming Investor Conferences
      Oct 22Yahoo FinanceACET
      Adicet Bio’s Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months

      Adicet Bio (NASDAQ:ACET) reported positive clinical data for prula-cel, its investigational allogeneic gamma delta CAR-T cell therapy, in patients with systemic lupus erythematosus, or SLE, including patients with lupus nephritis. The company said that, among evaluable lupus nephritis patients, 50%

      Oct 3Yahoo FinanceACET
      Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis - Slideshow
      Sep 30Seeking AlphaACET
      Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
      Sep 30Yahoo FinanceACET
      H.C. Wainwright raises Adicet Bio stock price target on lupus data
      Sep 29Investing.comACET
      Wedbush raises Adicet Bio stock price target on lupus trial data
      Sep 28Investing.comACET
      Adicet Bio Reports Positive Prula-cel Phase 1 Lupus Data as Pivotal Study Plans Advance

      Adicet Bio (NASDAQ:ACET) reported 12-month DORIS remission in 54% of evaluable systemic lupus erythematosus patients and complete renal response in 50% of evaluable lupus nephritis patients, supporting plans to begin pivotal study start-up activities in the fourth quarter of 2026. Key Investor TakeawaysAdicet Bio (NASDAQ:ACET) reported positive prula-cel Phase 1 lupus data from 22 efficacy-evaluable patients, including 16 with lupus nephritis and six with extra-renal SLE.

      Sep 28Yahoo FinanceACET
      Adicet Bio Reports Phase 1 Prula-cel Data in Lupus Patients
      Sep 28Yahoo FinanceACET
      Adicet Bio reports lupus trial results, plans pivotal study
      Sep 28Investing.comACET
      Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
      Sep 28Yahoo FinanceACET
      Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
      Sep 25Yahoo FinanceACET
      12 Health Care Stocks Moving In Friday's After-Market Session
      Sep 25BenzingaACETONCO
      H.C. Wainwright reiterates Adicet Bio stock rating on data update
      Sep 21Investing.comACET
      Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High?

      The average of price targets set by Wall Street analysts indicates a potential upside of 258.2% in Adicet Bio (ACET). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

      Sep 3Yahoo FinanceACET
      Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?

      Here is how Adicet Bio, Inc. (ACET) and Centene (CNC) have performed compared to their sector so far this year.

      Sep 3Yahoo FinanceACET
      Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference
      Sep 2Yahoo FinanceACET
      Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

      REDWOOD CITY, Calif., August 31, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced it granted an inducement award on August 31, 2026.

      Aug 31Yahoo FinanceACET
      Adicet Bio receives FDA clearance for prostate cancer trial
      Aug 27Investing.comACET
      Analysts Offer Insights on Healthcare Companies: Adicet Bio (ACET) and Jazz Pharmaceuticals (JAZZ)

      Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.

      Aug 27The Globe and MailACETJAZZ
      Adicet Bio Announces FDA Clearance of IND Application for ADI-212
      Aug 27Yahoo FinanceACET
      Here's Why You Should Add ACET Stock to Your Portfolio Now

      Adicet Bio advances prula-cel in autoimmune diseases while pursuing new opportunities in prostate cancer and in vivo CAR-T.

      Aug 24Yahoo FinanceACET

      This is the newest page. Registered accounts read further back.